Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.71 |
| ▸ | NPY1R | P25929 | 11/20 | 0.71 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.71 |
| ▸ | NPY2R | P49146 | 7/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31222389 | 0.96 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL31222392 | 0.94 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31222409 | 0.94 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30404546 | 0.94 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL31222420 | 0.93 | NPY4R (0.69) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL30273392 | 0.93 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL29959235 | 0.93 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| Acetic Acid SCHEMBL29958972 | 0.92 | NPY4R (0.70) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL29871918 | 0.91 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL31222379 | 0.91 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2ROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | OPRL1, OPRK1, OPRM1 | NPY4R 20/4885NPY1R 38/4885NPY5R 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.